Status:
WITHDRAWN
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Lead Sponsor:
Haukeland University Hospital
Collaborating Sponsors:
Novartis
Conditions:
Hemochromatosis
Myelodysplastic Syndromes
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Hypothesis: Deferasirox can be used as a therapeutic agent to deplete the liver, heart and bone marrow of excess iron in patients with iron overload caused by myelodysplastic syndrome (MDS) and hemoch...
Detailed Description
The two most important causes of iron overload disease in humans are the iron-loading disorder hereditary hemochromatosis (HC), and transfusional siderosis in patients with chronic hematological disea...
Eligibility Criteria
Inclusion
- Patients with hemochromatosis, aged \> 30 years, C282Y- homozygote, with serum-ferritin =/\> 1000 µg/L
- Patients aged \> 18 years with verified low-risk or intermediate-1 risk of myelodysplastic syndrome, with normal cytogenetics and serum-ferritin \> 1500 µg/L, or with a transfusion history of =/\> red- blood-cell-transfusions.
Exclusion
- Previous or current venesection
- MDS patients eligible for hematopoietic stem cell transplantation
- Subject complies with one or more of the following standard exclusion criteria for MRI examination;
- If the patient has a pacemaker.
- If the patient has a neurostimulator
- If the patient has a "aneurismeclips"
- If the patient has a foreign object in the eye. If yes, what object.
- If the patient has a cochlea-/earimplant.
- If the patient has a V/P shunt.
- If the patient is claustrophobic.
- If the patient has an artificial heart valve.
- If the patient has known renal failure, eGFR \<30.
- If the patient has or will have a liver transplantation.
- Other: metal prostheses, metal implant
- Presence of inflammation (CRP ≥ 5 mg/L)
- Presence of proteinuria or creatinine \> 2 x UNL (Upper Normal Limit)
- Estimated glomerular filtration rate (GFR) \< 60 mL/min
- ALAT, ASAT, GT or ALP \> 2 x ULN ( Upper Normal Limit)
- ALAT \> 90 U/L for women, ALAT \> 140 U/L for men
- ASAT \> 70 U/L for women, ASAT \> 90 U/L for men
- ALP \> 210 U/L for women and men
- GT \> 90 U/L for women ≤ 40 years, GT \> 150 U/L for women \> 40 years
- GT \> 160 U/L for men ≤ 40 years, GT \> 230 U/L for men \> 40 years
- Acute or chronic hepatitis
- Patients with chronic liver disease Child Pugh Class B and C
- Chronic skin disease with rash
- Estimated survival \< 6 months
- Prior or concomitant treatment with other iron chelator therapies within 6 weeks of screening
- History of non-compliance to medical regimens, or considered potentially unreliable and/or not cooperative
- Uncontrolled diabetes, defined as glycolated hemoglobin (HbAlc) \> 8.5%
- Presence of cataracts or hearing loss disease
- Presence of a surgical or medical condition which might significantly alter absorption, distribution, metabolism or excretion of study drug
- Planned in-hospital surgeries during the course of the study
- Subjects who are pregnant, breast-feeding, or intending to become pregnant
- Hypersensitivity to the active substance or the excipients in drug product
- Any other reason why, in the opinion of the investigator, the patient should not participate (e.g. serious heart disease, infection, cancer, etc).
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01892644
Start Date
May 1 2013
End Date
January 1 2017
Last Update
April 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haukeland University Hospital, Clinical Trial Unit
Bergen, Norway, 5021